Ishita Drugs Falls 3.14%: Valuation Concerns and Margin Pressures Shape the Week
2026-11-07 17:07:47Key Events This Week 2 Nov: Stock opens at Rs.72.00 amid Sensex rally 5 Nov: Q2 FY27 results reveal margin pressures; stock surges 8.32% 6 Nov: Valuation shift signals price attractiveness erosion; stock falls 8.96% 6 Nov: Week closes at Rs.71.00, down 3.14% vs Sensex +7.15% Week OpenRs.72.00 Week Close<div class="sta...
Read More
Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-10-30 08:01:15Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent downgrade in its overall Mojo Grade to Strong Sell. This repositioning in price-to-earnings and price-to-book value metrics offers investors a nuanced perspective on the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.
Read MoreIshita Drugs Falls 4.34%: 2 Key Factors Driving the Weekly Decline
2026-10-17 17:05:07Key Events This Week 12 Oct: Stock opens steady at Rs.76.00 amid weak Sensex 13 Oct: Downgrade to Strong Sell announced, stock falls 1.45% 15 Oct: Stock rebounds 2.80% to Rs.77.00 on low volume 16 Oct: Valuation shift to fair grade, stock drops 5.58% Week OpenRs.76.00 Week CloseRs.72.70<d...
Read More
Ishita Drugs & Industries Ltd: Valuation Shifts Signal Changing Price Attractiveness
2026-10-16 08:00:32Ishita Drugs & Industries Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating, reflecting evolving market perceptions and sector dynamics. Despite a recent day gain of 2.80%, the micro-cap pharmaceutical company faces valuation challenges when compared to its peers, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios signalling a more tempered price attractiveness.
Read More
Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals
2026-10-14 08:15:30Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 13 Oct 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The micro-cap pharmaceutical company’s recent performance and valuation metrics have raised concerns among analysts, prompting a reassessment of its outlook across quality, valuation, financial trend, and technical parameters.
Read More
Ishita Drugs & Industries Ltd: Valuation Shifts Signal Changing Price Attractiveness
2026-09-28 08:00:32Ishita Drugs & Industries Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid mixed financial performance. Despite a recent uptick in share price, the company’s micro-cap status and relative valuation metrics warrant a cautious approach for investors navigating the Pharmaceuticals & Biotechnology sector.
Read More
Ishita Drugs & Industries Ltd: Valuation Shifts Signal Renewed Price Attractiveness
2026-09-17 08:00:34Ishita Drugs & Industries Ltd has recently undergone a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade. Despite a challenging market environment reflected in a 5.08% drop in share price on 17 Sep 2026, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector.
Read More
Ishita Drugs & Industries Ltd: Valuation Shifts Signal Renewed Price Attractiveness
2026-09-02 08:00:40Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven primarily by a recalibration of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This development comes amid a challenging pharmaceutical sector landscape and a micro-cap status that continues to influence investor sentiment. A detailed analysis of these valuation changes against historical and peer benchmarks reveals a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology space.
Read More
Ishita Drugs & Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-08-27 08:00:34Ishita Drugs & Industries Ltd has recently seen a notable shift in its valuation parameters, moving from a fair to an attractive rating. Despite a modest decline in share price and a challenging sector backdrop, the company’s improved price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers suggest a compelling entry point for investors seeking value in the pharmaceuticals and biotechnology micro-cap space.
Read MoreOutcome Of Board Meeting Held On 03Rd November 2026
03-Nov-2026 | Source : BSEUnaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 alongwith limited review report issued by the statutory auditors of the Company.
Board Meeting Outcome for Outcome Of Board Meeting Held On 03Rd November 2026
03-Nov-2026 | Source : BSEBoard of Directors of Ishita Drugs and Industries Limited at its meeting held today i.e. Tuesday 03rd November 2026 have 1. Approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 along with the Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. 2. Discussed the upgradation project of manufacturing facility for compliance with Revised Schedule M.
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 For The Quarter Ended 30Th September 2026
28-Oct-2026 | Source : BSEIshita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2026.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available